INTRODUCTION {#sec1-1}
============

Infertility affects over 50 million couples, and potentially as many as 186 million people worldwide suffer from fertility issues. Due to limitations regarding precise numbers, the male factor is expected to contribute toward approximately half of all infertility cases.[@ref1] The current diagnostic approaches focus on analysis of standard semen parameters: motility, morphology, and sperm count. Regardless, up to one-third of infertile males are considered as possessing idiopathic sperm abnormalities.[@ref2][@ref3] However, this issue becomes difficult to address as some sperm donors who do not show abnormalities in semen parameters display issues with conception. It is suggested that, in some cases, molecular defects leading to conception failure may be the root of the problem. Increasing evidence indicates that basic semen analysis does not fully encompass the potential of male fertility.[@ref3][@ref4]

For this reason, plausible sperm biomarkers, such as the expression patterns of sperm RNAs and protein, need to be evaluated instead of reliance on the standard semen parameters. These factors could play a functional role after delivery to the oocyte, or they may play a part in modulation of gene expression processes. The amount of particular RNAs and/or proteins may be a distinguishing factor between fertile and infertile men, even when the latter present normal semen parameters.[@ref3] In this manner, molecular biomarkers are thought to be a promising area of specific and suitable therapeutic tools in fertility issues' exploration.[@ref4]

Sperm viability parameters are essential for successful conception, and they depend on complex orchestration of biological systems. It is postulated that steroid hormones play a crucial role in the spermatogenesis process.[@ref5][@ref6][@ref7][@ref8] Previously, attention was focused on estrogens, androgens, and their cognate receptors. Steroid hormones can affect target cells via genomic and/or nongenomic mechanisms, creating a network of proteins involved in signal transduction.[@ref9][@ref10] Estrogen plays a critical role in the male reproductive system as it is essential for its proper development as well as the process of spermatogenesis.[@ref6][@ref11][@ref12][@ref13] It has been suggested that the target cells for estrogen can also be human sperm cells. Recent studies demonstrated that estrogens modulate sperm motility, capacitation, and acrosome reaction.[@ref14][@ref15][@ref16][@ref17][@ref18] Estrogens affect target cells via specific estrogen receptors (ESRs): ESR1 and ESR2. Spermatozoa possess both forms of the ESRs as well as aromatase, the enzyme that converts testosterone to estrogen, indicating that these proteins are key factors in the male reproductive system.[@ref19][@ref20][@ref21][@ref22] Our previous studies showed the presence of ESRs in the midpiece region of sperm, suggesting their importance in the context of mitochondrial function.[@ref21][@ref23]

Novel findings indicate the primary role of proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) in crosstalk between cellular processes mediated via ESR. Additionally, the mechanistic relationship between G protein-coupled estrogen receptor (GPER30) and the estrogen-related signaling pathway has been reported.[@ref24] Because many environmental factors are described as endocrine estrogen disruptors, which may bind to ESR, GPER30, and the androgen receptor,[@ref25] it is essential to trace the molecular pathway of estrogen action in males. As a result, PELP1 would be placed among the molecules involved in signal modulation of rapid estrogen signaling, particularly in sperm cells.

PELP1 is present both within the cell nucleus and cytoplasm. The genomic action of PELP1 may influence gene expression by binding to H3 and H4 histones and, as a consequence, remodels chromatin structure. Nongenomically, PELP1 is engaged in estrogen-dependent signal transduction based on a social network of phosphorylated protein complexes.[@ref26][@ref27][@ref28] It also participates in ribosome biogenesis and serves as a protein--protein mediator in various cellular processes.[@ref29][@ref30] *PELP1* RNA levels and protein expression in mature sperm cells are under scrutiny.[@ref31]

Taking into consideration the influence of environmental estrogen-like compounds on the biology of male reproductive system and sperm cells, the aim of our study was to determine a PELP1 expression pattern and compare it with sperm parameters. As postulated, this protein is essential for estradiol-mediated, extranuclear response, and thus plays a crucial role in signal transduction in spermatozoa. We analyzed *PELP1* mRNA and protein concentrations in pooled semen samples. First of all, we confirmed its presence in sperm, and then we estimated its cellular localization in the spermatozoa and determined the proportion of PELP1 in subjects presenting normal and abnormal semen parameters.

MATERIALS AND METHODS {#sec1-2}
=====================

 {#sec2-1}

### Ethical approval statement {#sec3-1}

The Institutional Review Board at the Poznan University of Medical Sciences, Poznan, Poland, approved this study (No. 553/13). Written informed consent was obtained from each participant.

### Materials {#sec3-2}

Semen samples were obtained from 178 men at the Division of Infertility and Reproductive Endocrinology of Poznan University of Medical Sciences. All participants were of Caucasian descent. All patients have been undergoing the diagnostic procedures due to infertility of unknown cause. Varicocele, prostate dysfunction, vas deferens obstruction, as well as metabolic diseases were excluded.

Semen samples of 43 men, aged 18--45 years (median age 33 years), were evaluated according to the World Health Organization (WHO) guidelines for normozoospermia: concentration above 15 × 10^6^ sperm ml^−1^, at least 58% live sperm, \>32% sperm showing progressive movement, more than 4% spermatozoa with normal morphology, and a leukocyte content of \<10^6^ cells ml^−1^.[@ref32] Seventeen samples were classified as normozoospermic according to the WHO standards and 26 samples which did not meet anyone of above-mentioned criteria, thereby, were qualified as abnormal (**Supplementary Table 1**)

###### 

Demographic data and comparison of semen characteristics

###### 

Click here for additional data file.

All 43 semen samples used for Becton Dickinson fluorescence-activated cell sorting (FACSCalibur™; Becton-Dickinson, Franklin Lakes, NJ, USA) analyses were obtained from each patient. Only one sample from each patient was used for the analysis. Sperm smears were prepared using 10 μl of the whole semen volume, and the remaining part was examined by FACSCalibur™ flow cytometry (Becton-Dickinson). Further investigations were performed at the Cell Biology Department of Poznan University of Medical Sciences. A schematic diagram describing semen sample acquisition is shown in [**Figure 1**](#F1){ref-type="fig"}.

![Schematic diagram of the sperm analysis procedure. Analysis of pooled semen samples (top) and individually analyzed donations (bottom). RT-qPCR: reverse transcription-quantitative polymerase chain reaction.](AJA-20-425-g001){#F1}

### mRNA and protein presence validation {#sec3-3}

Due to the small amount of RNA in spermatozoa, nine separate trials of pooled semen samples were obtained from 12--18 donors (*n* = 135). Half of the pooled sample volume was used for RNA extraction and the other half for protein isolation. Swim-up technique was used to obtain a pure fraction of sperm cells from each sample according to the WHO guidelines.[@ref32]

### Analysis of PELP1 mRNA expression {#sec3-4}

Total RNA was isolated using TriPure isolation reagent (Roche, Basel, Switzerland) according to a modified Chomczynski and Sacchi method.[@ref33] The modifications included repeated TriPure isolation step and RNA precipitation at −80°C instead of room temperature (RT) incubation, followed by nucleic acid concentration using a silica matrix column system (ZymoResearch, Irvine, CA, USA). Additionally, the repeated TriPure step during RNA extraction prevented DNA contamination. RNA sample quantity and purity was assessed by measuring absorbance (NanoDrop ND-1000 spectrophotometer; Thermo Fisher Scientific, Waltham, MA, USA) at A260 nm, A230 nm, and A280 nm; and the A230/260 and A260/280 ratios showed that all samples met the criteria for purity (both ratios ranged from 1.9 to 2.0). To evaluate sample integrity, the ribosomal RNA bands were analyzed by 0.8% agarose gel electrophoresis in denaturing conditions of 1 μg RNA in 1 × FA buffer (pH 7.0, 1 mmol l^−1^ ethylenediaminetetraacetic acid, 5 mmol l^−1^ sodium acetate, 20 mmol l^−1^ 3-(N-morpholino)-propanesulfonic acid \[free acid; Sigma-Aldrich, Saint Louis, MO, USA\]) and 0.8% paraformaldehyde (Avantor Performance Materials Poland S.A., Gliwice, Poland) providing denaturing conditions in the presence of ethidium bromide (Sigma-Aldrich).

The reverse transcription reaction was performed according to the Transcriptor reverse transcriptase manufacturer protocol (Roche). The total reaction volume was 10 μl. In the first step, 500 ng of total cellular RNA, DNase, RNase, pyrogen-free water, and 5 pmol μl^−1^ universal oligo (dT)~10~ primer were combined, and the samples were denatured at 65°C for 10 min then cooled on ice. Next, each sample was complemented with 5 pmol μl^−1^ of each deoxynucleotide triphosphates (dNTPs), 10U for reaction (rxn) ribonuclease inhibitor, 1 × buffer (Transcriptor RT buffer; Roche, Basel, Switzerland), and 10U for rxn of reverse transcriptase. The following thermal profile was applied: 25°C for 10 min, 55°C for 60 min, then 5 min at 85°C. cDNA was immediately used for quantitative polymerase chain reaction (qPCR) or stored at −20°C until further analysis (but no longer than 1 week).

To establish RNA expression, the LightCycler® 2.0 carousel glass capillary-based system was applied (Roche). Primer sequences and TaqMan® hydrolysis probe position for the gene of interest (GOI) were determined using Roche Universal Probe Library Assay Design Center (<https://lifescience.roche.com/en_pl/brands/universal-probe-library.html>, last accessed on September 28, 2017). The hypoxanthine-guanine phosphoribosyltransferase (*HPRT*) gene encoding hypoxanthine-guanine phosphoribosyltransferase was served as an internal control (Roche assay N° 05046157001). The reaction mixture in a total volume of 20 μl contained 5 μl template cDNA (obtained in the reverse transcription reaction step), 1 × LightCycler® FastStart TaqMan® Probe Master (Roche), 0.1 μmol l^−1^ hydrolysis probe (0.2 μmol l^−1^ in the case of GOI), and 0.5 μmol l^−1^ gene-specific primers. The Universal Probe Library (UPL) probe and the sense and antisense primers for the GOI were as follows: probe \#62 (Roche cat. N°: 04688619001) and 5'-GCACTGTGTGTCTTGGCTTC-3' and 5'-GAGGAGGTCCCTCAGGACA-3'. The primers were designed so that they annealed in two different exons spaced by a 7.9-kb intron. We used the standard cycling and acquisition reaction profile for UPL probes.[@ref34] Each reaction was performed in duplicate on independently synthetized cDNA. Samples were sequenced to confirm their identity with those deposited in the Nucleotide Database of National Center for Biotechnology Information (GenBank N^o^: NM_014389.2).

### PELP1 protein detection {#sec3-5}

Sperm cells were suspended in an appropriate volume of isolation buffer (80% phosphate-buffered saline \[PBS; PAN-biotech, Aidenbach, Germany\]); 10% protein extraction and immunoprecipitation 1 × radio-immunoprecipitation assay (RIPA) buffer (Merck Millipore, Darmstadt, Germany); and 10% protease inhibitor cocktail (Sigma-Aldrich). The samples were incubated for 15 min at 4°C with gentle shaking, then cells were centrifuged (Centrifuge 5812R; Eppendorf, Hamburg, Germany) at 12 000 *g*, 4°C, l5 min., and the supernatants containing protein extracts were used for western blot analysis. Quick Start Bradford Dye Reagent (BioRad, Hercules, CA, USA) and spectrophotometer (NanoDrop ND-1000; Thermo Fisher Scientific) were used for colorimetrical measurement of extracted proteins (595 nm wavelength) and referred to decimal dilution series of bovine serum albumin fraction V (BSA V; Roche).

Thirty micrograms of extracted proteins were separated using 12% SDS-PAGE running buffer (25 mmol l^−1^ Tris, 192 mmol l^−1^ glycine, 0.1% SDS, pH 8.3 \[LabEmpire, Rzeszow, Poland\]; 200V, 40 min, RT) and subsequently transferred to activated Hybond-P polyvinylidene fluoride membrane (GE Healthcare Europe, Little Chalfont, UK) in transfer buffer (1 × SDS-PAGE running buffer supplemented with 20% methanol; 300 mA, 90 min, RT). After blotting, membranes were incubated for 1 h at 4°C in Tris-buffered saline with Tween 20 (TBST) buffer (5% Blotto blocking reagent solution \[BioRad\]; 1 × TBST). Protein detection was evaluated using primary polyclonal anti-PELP1 rabbit antibody (Bethyl Laboratories, Montgomery, TX, USA) followed by incubation with polyclonal anti-rabbit alkaline phosphatase-conjugated goat secondary antibody (Sigma-Aldrich), both at a 1:2500 dilution (200 rpm orbital shaker, 1 h, 4°C). Each time, unbounded antibodies were rinsed three times in TBST buffer (200 rpm, 10 min, RT). Glyceraldehyde 3-phosphate dehydrogenase protein (GAPDH) extracted from spermatozoa, as well as from the ovarian cancer cell line OVCAR-3 (ATCC, Manassas, VA, USA), was used as internal and external positive control for PELP1 expression. Visualization was performed using the BCIP®/NBT-Blue liquid substrate system for membranes (Sigma-Aldrich). Membranes were digitized using G:BOX Chemi system (Syngene, Cambridge, UK). Western blots were repeated in triplicate for all 9 pooled samples.

### Immunocytochemistry {#sec3-6}

Smears were fixed on glass microscope slides in a 4% buffered paraformaldehyde solution (Avantor Performance Materials Poland S.A.) for 10 min at RT. In order to retrieve antigens, the slides were boiled in a microwave oven twice (2 × 10 min, 200W) in citrate buffer (pH 6.0, 0.1 mol l^−1^ citric acid solution, 0.1 mol l^−1^ sodium citrate solution; Avantor Performance Materials Poland S.A.) and then cooled at RT. In order to block endogenous peroxidase activity, slides were incubated for 3 min in 3% hydroxyperoxide solution (Avantor Performance Materials Poland S.A.). To avoid nonspecific antibody binding, the slides were placed in TBST buffer (containing 3% BSA) for 1 h at RT. To evaluate PELP1 protein localization, the same primary antibodies (Bethyl Laboratories) as for western blot were used at a 1:500 dilution. Incubation was carried out overnight at 4°C.

Subsequently, the slides were rinsed three times for 15 min in TBST buffer. In order to identify cellular localization of the antigen, the slides were processed with commercial Dako EnVision^+^ System HRP (DAB) kit (Dako, Glostrup, Denmark) containing a horseradish peroxidase-conjugated anti-rabbit secondary antibody. The detection procedure was provided by the manufacturer. As positive controls, 3 μm dewaxed and rehydrated tissue specimen sections of ovarian cancer were used. Evaluation was performed under the Axiophot light microscope (Zeiss-Opton, Oberkochen, Germany).

### Flow cytometry {#sec3-7}

Cells were separated using a gradient isolation system (Sil-Select Plus, FertiPro N.V., Beernem, Belgium) according to the manufacturer\'s protocol. Sperm cells from the lower phase were harvested and pelleted (300 g, 10 min, RT), and spermatozoa were fixed in an appropriate volume of 4% buffered paraformaldehyde solution (1 h, RT) followed by centrifugation 10 min, 200 *g*, 4°C (Centrifuge 5415D, Eppendorf). Next, cells were permeabilized on ice for 20 min in 500 μl 0.1% saponin solution in PBS supplemented with 0.5% BSA. Samples were then centrifuged again under the same conditions, and 100 μl of PELP1 primary polyclonal antibodies were applied at a 1:500 dilution. The incubation period was 1 h on ice. Next, the solution was filled up with saponin (to the maximum volume of the 1.5 ml eppendorf tube), centrifuged (200 *g*, 5 min, 4°C), and washed with PBS. The next step was a 30-min incubation on ice in darkness with secondary goat anti-rabbit antibody conjugated with fluorescein (Santa Cruz Biotechnology Inc., Dallas, TX, USA) at a 1:100 dilution. Samples were then filled with saponin solution, centrifuged, and suspended in 500 μl PBS. In the negative control, samples omitted the primary antibody. For each experiment performed using BD FACSCalibur™ flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA), 10 000 cells were examined. The fluorescence dye was excited by argon laser (488 nm) and emission was measured in the FL1 channel (515--545 nm). All data were gathered and analyzed using BD CellQuest™ Pro software (version 5.2.l; Becton Dickinson). The FACS operator was blinded for the results of the semen analyses. The intensity of fluorescence of PELP1-positive cells derived from patients presenting abnormal semen parameters was compared to the values obtained from patients fulfilling the criteria for normozoospermia.

### Statistical analysis {#sec3-8}

Statistical analysis was performed using Statistica version 12 software for Windows (StatSoft Inc., Tulsa, OK, USA). To describe experimental results, mean ± standard deviation was used. The Shapiro--Wilk test was used for the normality of continuous variables distribution assessment. The Welch\'s *t*-test, as well as Mann--Whitney U-test, was applied. The correlation coefficient (*r*) between sperm parameters and mean fluorescent intensity was determined by the Spearman\'s rank correlation tests. Using the Medical plugin version 4.0 for Statistica software (StatSoft), the receiver operating characteristic (ROC) curve was created. Subsequently, Hanley and McNeil methods for ROC comparison were used for further analysis of the data and for calculation of the sensitivity and specificity of PELP1 quantification in relation to normal/abnormal semen quality. Data were considered statistically significant at *P* \< 0.05.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### PELP1 mRNA and protein validation {#sec3-9}

*PELP1* amplification was confirmed in all analyzed samples using specific primers and TaqMan® probes (Roche, assay N° 05046157001 for *HPRT*, and probe \#62 Roche cat. N°: 04688619001 for *PELP1*). The reaction product specificity was evaluated by electrophoretic separation in agarose gel, sequencing, and alignment analysis. Based on comparison with the molecular size marker Nova l00 (Novazym, Poznan Poland), bands were observed at a size corresponding to the *PELP1* mRNA fragment, in length of 100 bp ([**Figure 2**](#F2){ref-type="fig"}). The consensus sequence of the PCR product was confirmed by sequencing analysis and compared to the mRNA of human *PELP1*, transcript variant 1 (GenBank N^o^: NM_014389.2).

![Analysis of the *PELP1* transcripts in human spermatozoa. (**a**) Relative position of primers and \#62 TaqMan^®^ probe in *PELP1* coding sequence (7933 bp intron is indicated). (**b**) *PELP1* RT-qPCR amplification curves. (**c**) qPCR products visualized in agarose gel. 1, 3, 4: human spermatozoa; 2: ovarian cancer (positive control); M: DNA ladder. PELP1: proline-, glutamic acid-, and leucine-rich protein 1; RT-qPCR: reverse transcription-quantitative polymerase chain reaction.](AJA-20-425-g002){#F2}

Western blot analysis confirmed the presence of the PELP1 protein in sperm cells. Immunoreactive bands were observed at approximately 170 kDa, corresponding to the molecular weight of human PELP1. A weak signal was detected in the case of total cellular proteins isolated from swim-up prepared spermatozoa, while a stronger signal was observed in the positive control samples (proteins isolated from ovarian cancer cell line OVCAR-3). The 37 kDa bands of GAPDH reference protein were strongly immunoreactive in all cases ([**Figure 3**](#F3){ref-type="fig"}).

![Western blot evaluation of PELP1 in human sperm. (**a**) Thirty micrograms of proteins were separated using 12% SDS-PAGE; lines 1, 3, 4: proteins isolated from sperm cells, line 2: external positive control derived from ovarian cancer cell line (OVCAR-3) shows the strongest immunoreaction. (**b**) Immunoreactive bands of GAPDH protein samples (referring to PELP1 western blot) were used as loading control. Lanes 1, 3, 4: proteins isolated from sperm cells; lane 2: proteins derived from OVCAR-3; M: protein molecular weight marker. GAPDH: glyceraldehyde 3-phosphate dehydrogenase protein; PELP1: Proline-, glutamic acid-, and leucine-rich protein 1; SDS-PAGE: sodium dodecylsulfate-polyacrylamide gel electrophoresis.](AJA-20-425-g003){#F3}

### Expression pattern analysis {#sec3-10}

Immunocytochemical staining confirmed the presence of PELP1 protein in human sperm. In cells with normal morphology, strong immunostaining was observed in the midpieces. Likewise, in cells with disturbed morphology (of head, midpiece, and/or tail), PELP1 protein was mostly presented within midpieces. Nuclear PELP1 localization was observed in ovarian cancer tissue samples (positive control) ([**Figure 4**](#F4){ref-type="fig"}).

![PELP1 immunolocalization in human sperm (light microscope, original magnification ×100). (**a**) PELP1 within midpieces of human spermatozoa with normal morphology (indicated by arrows). (**b**) PELP1 in sperm cells with disturbed morphology. (**c**) Nonprimary antibody negative control. (**d**) Positive control reaction in ovarian cancer tissue. Scale bars = 5 μm in a--c, and 100 μm in d. PELP1: proline-, glutamic acid-, and leucine-rich protein 1.](AJA-20-425-g004){#F4}

FACS analysis quantified sperm with PELP1 expression. For each sample, 10 000 cells were analyzed. The intensity of fluorescence of PELP1-positive sperm was lower in normozoospermic semen in comparison to abnormal samples (42.78% ± 11.77% *vs* 61.05% ± 21.70% respectively; *P* = 0.014; [**Figure 5**](#F5){ref-type="fig"}). In all analyzed parameters, with the exception of viability and total motility, there were differences between mean fluorescence intensity (*P* ≤ 0.001). The mean expression level was higher in samples with abnormal semen parameters. In the analysis presented in **Supplementary Table 2**, the parameters described in each row were taken under consideration as the major subgroup determinant (*P* \< 0.01). A negative correlation was found between all sperm parameters and PELP1 expression. The correlation coefficients varied from −0.41 to −0.59 (*P* \< 0.01; **Supplementary Table 3** and [**Figure 6**](#F6){ref-type="fig"}). ROC curve analyses for the "normal/abnormal" semen categories revealed areas under the curve (AUC) for PELP1 quantification (0.781; *P* = 0.0001). The cutoff value of 42.15 made it possible to predict the abnormality in semen quality with a sensitivity of 88% and specificity of 65%.

![Flow cytometry analysis of the PELP1 in human spermatozoa of normal and abnormal semen samples. (**a**) Representative histogram of PELP1-positive sperm cells. Colors indicate samples obtained from different patients. (**b**) Bar graph of the fluorescence intensity of PELP1-positive cells. PELP1: proline-, glutamic acid-, and leucine-rich protein 1; FL1-H: fluorescence relative intensity (height) of PELP1 in channel 1 measured by flow cytometry.](AJA-20-425-g005){#F5}

###### 

Statistical analysis results of proline-, glutamic acid-, and leucine-rich protein 1 mean fluorescence intensity values and semen parameters

###### 

Click here for additional data file.

###### 

Correlation between semen parameters and proline-, glutamic acid-, leucine-rich protein 1 expression

###### 

Click here for additional data file.

![Correlation scatter plots of PELP1 fluorescence intensity and various semen parameters. Scatter plots display the correlation between PELP1 fluorescence intensity and (**a**) sperm concentration, (**b**) progressive motility, (**c**) total motility, (**d**) total sperm number, (**e**) sperm morphology, and (**f**) viability. PELP1: proline-, glutamic acid-, and leucine-rich protein 1.](AJA-20-425-g006){#F6}

DISCUSSION {#sec1-4}
==========

Our analysis of mRNA and protein expression revealed, for the first time, the presence of PELP1 in human spermatozoa using four precise, independent techniques. The qualitative presence of transcripts and protein was established by reverse transcription-polymerase chain reaction (RT-PCR) and western blot protocols, respectively. The cellular localization of PELP1 was investigated immunocytochemically. Quantitative analysis of PELP1-positive cells was performed using flow cytometry (FACSCalibur™; Becton Dickinson Biosciences).

Until this point, no studies have indicated the presence of PELP1 in spermatozoa. We suspect that PELP1 contributes to the biology of sperm cells. This protein is involved in both genomic and nongenomic pathways of estrogen signal transduction in somatic cells.[@ref35][@ref36][@ref37][@ref38][@ref39]

Besides the presence of RNA, the protein inheritance in mature sperm was confirmed by the western blot analysis. Detection of PELP1 protein can be supported by the presence of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) in the midpiece region of spermatozoa.[@ref40] PI3K is involved in estrogen action, transduced via ESRs. PI3K can influence the regulation of calcium channels through phosphatidylinositol (3,4,5)-trisphosphate and diacylglycerol. Those findings are interesting especially in the context of increased Ca^2+^ concentrations observed in the sperm in a quick/nongenomic response to estrogens.[@ref41] The PELP1 expression pattern observed using Axiophot light microscopy indicated its localization in the same region as PI3K in sperm with normal and abnormal parameters ([**Figure 4**](#F4){ref-type="fig"}). Considering studies reporting on different cellular localization of PELP1 (cytoplasmic *vs* nuclear), its function is compartment dependent.[@ref42]

Moreover, it has been reported that one ESR isoform can interact with a G-protein-coupled estrogen receptor located in the midpiece.[@ref19][@ref43][@ref44] Due to PELP1 interaction with ESR, such localization seems to be justified. The presence of ESRs and PELP1 in the same cellular region could be related to a potential role of estrogens in energy production for motility, capacitation reaction, and sperm fertilizing ability.

In this study, we did not observe significant differences in the PELP1 expression pattern regarding total motility and viability parameters. Surprisingly, in the case of other analyzed parameters, the percentage of PELP1-positive spermatozoa was higher in sperm samples with abnormal parameters. A negative correlation was observed between decreasing PELP1 expression and increasing sperm quality. This may be due to an excess of residual cytoplasm in disturbed sperm morphology or protein redistribution. Moreover, PELP1 was reported to induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, which is related to inflammatory signals that modulate macrophage activation.[@ref42] Taking all of these into account, this could lead to decrease of sperm parameters.

For the first time, our study demonstrates the presence of PELP1 in spermatozoa and its increased expression in sperm with abnormal parameters.

CONCLUSIONS {#sec1-5}
===========

This study demonstrates the presence of mRNA, protein, and cellular localization of PELP1 in ejaculated spermatozoa. Flow cytometry analysis showed that the percentage of sperm cells stained with PELP1 antibody is negatively correlated with increasing sperm quality. Thus, it might be a marker of impaired semen quality. To evaluate the exact role of PELP1 in male germ cell development, as well as in mature sperm physiology and pathology, further studies need to be conducted.
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